GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » Cash Flow from Investing

Verve Therapeutics (Verve Therapeutics) Cash Flow from Investing : $-29.33 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Verve Therapeutics spent $0.43 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $164.19 Mil on purchasing investments. It gained $122.99 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Verve Therapeutics spent $41.63 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Verve Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Verve Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verve Therapeutics Cash Flow from Investing Chart

Verve Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
-12.76 -51.13 -239.10 -155.96 27.69

Verve Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.39 33.03 -11.83 -8.89 -41.63

Verve Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Verve Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Verve Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verve Therapeutics  (NAS:VERV) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Verve Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.43 Mil. It means Verve Therapeutics spent $0.43 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Verve Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Verve Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Verve Therapeutics's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Verve Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Verve Therapeutics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Verve Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Verve Therapeutics's purchase of investment for the three months ended in Mar. 2024 was $-164.19 Mil. It means Verve Therapeutics spent {stock_data.stock.currency_symbol}}164.19 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Verve Therapeutics's sale of investment for the three months ended in Mar. 2024 was $122.99 Mil. It means Verve Therapeutics gained $122.99 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Verve Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Verve Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Verve Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Verve Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Verve Therapeutics's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Verve Therapeutics paid $0.00 Mil for other investing activities.


Verve Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Verve Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Verve Therapeutics (Verve Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Executives
Krishna Yeshwant director, 10 percent owner C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Allison Dorval officer: Chief Financial Officer C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Fred T. Fiedorek officer: Chief Medical Officer 55 BALDWIN LANE, PRINCETON NJ 08540
Joan Nickerson officer: Chief Administrative Officer C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Andrew Bellinger officer: Chief Scientific Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc. other: Member of 10% Group 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Sekar Kathiresan director, 10 percent owner, officer: Chief Executive Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Lonnel Coats director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman director, 10 percent owner DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Andrew D. Ashe officer: See Remarks C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Logos Global Management Lp 10 percent owner 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116

Verve Therapeutics (Verve Therapeutics) Headlines